The percentage area of PGP9.5 that contained Nav1.9 immunoreactivity varied greatly between the specimens sampled (Table 1), ranging from 5.42-13.39% (mean 9.16 ± 1.51 [SEM]%) in neuromas from patients with no symptoms of dysaesthesia, and 1.12-18.97% (mean 12.8 ± 2.38 [SEM]%) in neuromas from patients with symptoms of dysaesthesia. This evidence concerns the gene SCN11A and neuroma.